The Health Procurement Agency tenders proton therapy for 9.39 million euros

The Healthcare Procurement Agency of the Community of Madrid has opened the tender for the framework agreement for the provision of proton therapy treatment services to patients to whom the Ministry of Health of the Community of Madrid is obliged to provide healthcare. The resolution, dated September 30, 2026, is signed by the CEO of the organization and published in the OFFICIAL GAZETTE OF THE COMMUNITY OF MADRID number 245, dated October 14, 2026 (reference BOCM-20261014-38). The total estimated value of the contract amounts to 9,390,400 euros, with a base tender budget of 2,934,500 euros, VAT included.

The file is processed under number AM PA SER 27/2026 – A/SER-024389/2026 and corresponds to CPV code 85110000-3 (Hospital Services and related services). The contracting authority is the agency itself, with NIF V70797667 and address at calle Gran Vía, 30, 2nd floor, Madrid, and its main activity is healthcare. The announcement was sent to the Official Journal of the European Union on September 30, 2026, and the contract is not linked to projects funded by Union funds.

Three lots and 68 annual treatments

The framework agreement is divided into three lots, with a total of 68 cases per year and unit prices per treatment:

• Lot 1: proton therapy for adults over 26 years old; 37 annual treatments at 37,500 euros each, with an annual budget of 1,387,500 euros.
• Lot 2: proton therapy for children, adolescents, and young adults aged 26 or under without anesthesia; 15 treatments at 45,000 euros, 675,000 euros per year.
• Lot 3: proton therapy for children, adolescents, and young adults aged 26 or under with anesthesia; 16 treatments at 54,500 euros, 872,000 euros per year.

Variants are not permitted, and the submission of bids will be carried out exclusively by electronic means, with electronic invoicing.

Deadlines, guarantees, and award criteria

The procedure is open, with ordinary processing and a plurality of criteria. The evaluation is divided between price, up to 49 points, and other qualitative criteria evaluable through formulas, up to 51 points. Bidders must maintain their offer for two months from the opening of the proposals.

• Deadline for receipt of bids: until November 2, 2026, at 23:59 hours.
• Opening of envelope number 3 (economic proposal and documentation of automatic criteria): November 10, 2026, at 13:30 hours, at the agency’s headquarters; non-public act in accordance with article 157.4 of the LCSP.
• Final guarantee: 5 per 100 of the award amount excluding VAT for each based contract.
• Complementary guarantee: an additional 5 per 100 in case of an abnormal or disproportionate proposal.

Validity and appeals regime

The contract shall be valid for 12 months from the day following its formalization, extendable up to 36 months with the extension provided for in the specifications. The special execution conditions and the requirements for qualification and solvency are detailed in clause 1 of the Particular Administrative Clauses Specifications, available on the Procurement Portal of the Community of Madrid.

A special appeal in procurement matters may be filed against the tender before the Administrative Tribunal for Public Procurement of the Community of Madrid, located at calle Manuel Cortina, 2, 5th floor, annex building, Madrid, within a period of 15 business days in accordance with article 50 of Law 9/2017 on Public Sector Contracts. The resolution is signed by José Nieves González, chief executive officer, by delegation of the Board of Directors agreed upon on August 27, 2024.

The tender guarantees the continuity of care for a high-complexity oncological treatment that is not provided in all hospitals and requires travel outside the region. With a volume of 68 annual cases and an estimated amount of 9.39 million euros, the framework agreement establishes homogeneous prices and conditions for all public healthcare in Madrid and reinforces specific care for pediatric and young patients, who are the most sensitive to radiation and the side effects of the therapy.

Source: OFFICIAL GAZETTE OF THE COMMUNITY OF MADRID, no. 245, of October 14, 2026, section I.D (Announcements, Ministry of Health), pp. 204-206 (official reference: BOCM-20261014-38).